Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
Research Report: Stock codeG
  17-01-2019 (�|)    CSPC Pharmaceutical (1093.HK) - Some drugs may face price-cut risks while current valuation is attractive enough
  16-01-2019 (�T)    CSPC Pharmaceutical (1093.HK) - Some drugs may face price-cut risks while current valuation is attractive enough
  15-01-2019 (�G)    CSPC Pharmaceutical (1093.HK) - Some drugs may face price-cut risks while current valuation is attractive enough
  03-09-2018 (�@)    CSPC Pharmaceutical (1093.HK) - Comments on 18H1 Results
  31-08-2018 (��)    CSPC Pharmaceutical (1093.HK) - Comments on 18H1 Results
[1 / @4]
CSPC Pharmaceutical(1093)
  Share this articleG    
Recommendation on   17-01-19 
Recommendation BUY
Price on Recommendation Date $ 12.060
Suggested purchase price N/A
Target Price $ 21.000
Weekly Special - 601021.CH SPRING Airlines
Written by: Eurus Zhou( Research Analyst )
+852 2277 6515


CSPC Pharmaceutical (1093.HK) - Some drugs may face price-cut risks while current valuation is attractive enough

Investment Summary

Recently the share price fell to 2017 level, with current PE ratio of 26.5x, which makes the stock attractive, considering CSPC is pharmaceutical leader in HK market. Yesterday, the management stated that in 2019E the group's earnings would increase by 20% to 30%, and the sales of NBP products (®¦¥²´¶²£«~) would increase by 25% to 30%. However, as some drugs still have potential price-cut risks in future GPO, we lower 2019 EPS forecast to be HK$0.70, based on 30x target PE, get target price of HK$21.0, and suggest buying during price trough.

Business Overview

2019 growth guidance is announced. The management announced that in 2019E the group's earnings would increase by 20% to 30%, and the sales of NBP products (®¦¥²´¶²£«~) would increase by 25% to 30%.

Some products face price-cut risks. We have noticed that in the pilot cities, CSPC abandoned the bid because of the low price in the second round of price negotiations. We thus estimate that CSPC may be barely affected GPO and rapid earnings growth may go on. However, Ou Lai-Ning appeared in the GPO negotiation list in Guangzhou, so we still highlight that there may be potential price-cut risks in future. Therefore, we lowered the revenue forecast of Oulaining and mildly increased the expense ratio to reflect the potential increase in the overall sales expenses.

18Q3 growth slowed down. In the first three quarters, the company recorded sales revenue of HK$15.85bn, up by 41.4% yoy (18H1 41.4%), and profit attributable to shareholders was approximately HK$2.73bn, up 33.8% yoy (18H1 41.1%). By business segments, finished drugs remained strong, with sales revenue of HK$12.35bn, an increase of 51.1% yoy. Among them, innovative drugs recorded sales revenue of approximately HK$7.543bn, up 62.1% yoy; generic drugs recorded sales revenue of HK$4.811bn, up 36.6% yoy. On API business, the average selling price of vitamin C remained at a high level, but due to recovering market production capacity and supply, ASP began to fall in the third quarter. The total supply and demand in the antibiotic market is roughly balanced.

Acquired R&D companies and product rights to enhance R&D pipelines. In Jan, one subsidiary, Ouyi, will receive the exclusive development and commercialization rights of Hangzhou Yingchuang to license small molecule products in China and US. CSPC will pay an exclusive license fee of RMB25mn as a down payment and development milestone payments of RMB200mn, and to pay sales royalties based on sales amount. Five innovative oncology small-molecule drug candidates are attained. In addition, the company acquired 100% equity of Yongshun Technology Development Ltd. at a consideration of RMB252.88 mn. Yongshun is mainly engaged in R&D of innovative monoclonal antibodies for targeting tumor antigens and immunotherapy of various kinds of cancers. At present, these three products have received IND approvals from NMPA. The acquisition will help enrich the CSPC's pipeline in the field of biopharmaceuticals and strengthen overall R&D capabilities.

Valuation & Risks

We give 2019 target price of HK$21.0. Current PE is about 26.5x. Considering that CSPC is a leader in Hong Kong stock market, we highlight that the current price is attractive. 19E EPS is forecasted to be HK$0.70, based on a target PE of 30x, and the target price is HK$21.0.

Risks include: risk of drug development failure; sales expansion is less than expected; costs are rising.Figure: 18H1 results by segments


Click Here for PDF format...

Back to Top

Information contained herein is based on data obtained from recognized statistical services, issuer reports or communications, or other sources believed to be reliable. However, we do not verify such information. We do not guarantee its accuracy or completeness, nor do we take responsibility for any loss occasioned by reliance placed upon the contents hereof. Any statements nonfactual in nature constitute only current opinions, which are subject to change. Phillip Securities (HK) Ltd (or one of its affiliates) or their officers, directors, analysts, or employees may have positions in securities or commodities referred to herein, and may, as principal or agent, buy and sell such securities or commodities. An employee, analyst, officer, or a director of Phillip Securities (HK) Ltd, or its affiliates, may serve as a director for companies mentioned in this report. Neither the information nor opinion expressed in this report shall constitute a solicitation to buy or sell any securities. There may be instances when fundamental, technical, and quantitative opinions may not be in concert. This firm (or one of its affiliates) may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned in this report.
There are risks inherent in international investments, which may make such investments unsuitable for certain clients. These include, for example, economic, political, currency exchange rate fluctuations, and limited availability of information on international securities. We recommend that you obtain the advice of your Financial Advisor regarding this or other investment in order to conform to your financial resources and risk preference

Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]